Угандийский ученый подал семь заявок на патенты для новых мРНК-вакцин против рака

For a cancer patient who has endured diagnosis, treatment and the anxious wait that follows, one question can overshadow almost everything else: will the cancer come back? A new set of cancer-vaccine technologies being developed in Uganda is attempting to tackle that problem precisely. Seven patent applications filed in the United States in August describe experimental messenger RNA, or mRNA, vaccine technologies designed to help the immune system recognize molecular features associated with particular cancers. The long-term ambition is significant: instead of waiting for some cancers to return after treatment, scientists hope vaccines of this kind could train the body’s immune system to recognize and attack cells carrying particular cancer-related molecular changes. But that possibility remains a scientific ambition, not a treatment currently available to patients. The seven applications, filed with the US Patent and Trademark Office between August 18 and 25, were spearheaded by Ugandan scientist Dr Matthias Magoola, founder of Dei BioPharma. They cover technologies aimed at molecular targets associated with several cancers, including some forms of leukaemia, brain cancer and acute myeloid leukaemia, as well as tumours associated with RAS and TP53 mutations and cancers driven by the human papillomavirus, or HPV. Behind the complicated scientific language is a relatively simple idea: identify something distinctive about a cancer cell and teach the immune system to recognize it. “Our ambition is global and deliberately long-term: to develop a modular immune platform capable of addressing the molecular drivers behind an expanding share of human cancers,” Magoola said in a statement announcing the filings. “These filings are an effort to build, target by target, the scientific and manufacturing foundation that will make many cancers preventable and controllable or less likely to return.” What is being proposed is not a single injection that would suddenly prevent or cure every form of cancer. Cancer is not one disease. Tumours can be driven by different genetic alterations, even when they occur in the same part of the body. The approach described in the patent filings attempts to deal with that complexity by developing a collection of pre-manufactured vaccine candidates aimed at molecular changes that repeatedly appear among groups of patients. A patient would potentially be matched to a vaccine according to the molecular characteristics of his or her tumour and, where necessary, an immune-system feature known as human leukocyte antigen, or HLA, type. That represents an important distinction. Traditionally, ordinary people understand cancer according to where it appears: breast cancer, brain cancer, cervical cancer or lung cancer. The proposed vaccine technology instead looks inside the tumour for particular molecular abnormalities that could serve as targets for the immune system. One application, for example, targets BCR-ABL, a genetic abnormality associated with particular forms of leukaemia. Another targets EGFRvIII, an abnormality found in some brain tumours. A third concerns NPM1 in a molecularly defined form of acute myeloid leukaemia. Other applications cover RAS-mutant tumours occurring across different organs, a particular TP53 mutation and HPV16/18- associated cancers. A seventh covers a broader platform intended to support several target-specific vaccine products. In practical terms, the ambition is to classify some patients not simply by where their cancer is found, but by what is driving it biologically. WHY MRNA MATTERS The technology uses messenger RNA, better known as mRNA. The basic principle became widely familiar during the Covid-19 pandemic, when mRNA vaccines were used to give cells temporary genetic instructions that allowed the immune system to learn to recognize a target. Cancer presents a far more complicated challenge. Instead of teaching the immune system to recognise a virus circulating between people, a cancer vaccine must help it distinguish abnormal tumour cells from the patient’s own healthy cells. According to the material supporting the Ugandan programme, candidate targets are therefore subjected to a strict test: they should recur among a defined group of patients, should not be present in essential normal tissue and should naturally be displayed by tumour cells. The aim is to give the immune system something sufficiently distinctive to attack. The technology could potentially be particularly relevant after conventional treatment, when surgery, chemotherapy, radiotherapy or other treatment has removed or destroyed most detectable cancer but microscopic cancer cells may remain. That condition, known as minimal residual disease, can matter because remaining malignant cells may eventually multiply and cause cancer to return. Dei BioPharma says recurrence prevention is one of the areas it intends to consider when deciding which vaccine candidates to prioritize. FROM A PATENT TO A PATIENT IS A LONG ROAD For patients and families, however, one distinction is essential. A patent filing is not the same thing as an approved cancer vaccine. A patent application seeks intellectualproperty protection for an invention. It does not, by itself, establish that the proposed treatment is safe, that it works in humans, or that regulators have approved it for patients. Those questions require scientific development, laboratory work and, ultimately, clinical testing and regulatory review. The significance at this stage is different: sophisticated cancer-vaccine research and intellectual property are being pursued from a biotechnology programme anchored in Uganda, in a field attracting intense international scientific interest. Magoola has previously co-authored work proposing criteria for identifying molecular targets for cancer vaccines. According to the company, he has more than 100 US patent applications associated with his work, about 70 of which have been published by the USPTO. The latest seven applications extend that work towards a portfolio of possible cancervaccine targets.